The ClinGen Evidence Repository is an **FDA-recognized human genetic variant database** containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Variant: NM_000552.5(VWF):c.2411G>T (p.Cys804Phe)

Version: 1.0

CA114168

313 (ClinVar)

Gene: VWF (HGNC:7450)
Condition: von Willebrand disease type 2N (MONDO:0015631)
Inheritance Mode: Autosomal recessive inheritance
UUID: e928df71-3a57-4f25-9303-36b69f384f15
Approved on: 2025/2/4
Published on: 2025/2/5

HGVS expressions

NM_000552.5(VWF):c.2411G>T (p.Cys804Phe)
NM_000552.5:c.2411G>T
NC_000012.12:g.6044322C>A
CM000674.2:g.6044322C>A
NC_000012.11:g.6153488C>A
CM000674.1:g.6153488C>A
NC_000012.10:g.6023749C>A
NG_009072.1:g.85349G>T
NG_009072.2:g.85349G>T
ENST00000261405.10:c.2411G>T
ENST00000261405.9:c.2411G>T
ENST00000538635.5:n.421-50388G>T
NM_000552.3:c.2411G>T
NM_000552.4:c.2411G>T

Likely Pathogenic

Met criteria codes 5

PP3 PM3_Supporting PM2_Supporting PP4_Moderate PS3

Evidence Links 1

Expert Panel

von Willebrand Disease VCEP

Criteria Specification Information

Criteria Specification: *ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF Version 1.0.0*
Criteria Specification Approval History
Criteria Specifications for this VCEP

Evidence submitted by expert panel

von Willebrand Disease VCEP

The NM_000552.5(VWF):c.2411G>T (p.Cys804Phe) missense variant is absent from gnomAD v4.1 (PM2_Supporting). The computational predictor REVEL gives a score of 0.935, which is above the ClinGen VWD VCEP threshold of >0.644 and predicts a damaging effect on VWF function (PP3). Factor VIII binding assay performed with the C804F recombinant mutant showed severely impaired binding indicating that this variant has a damaging effect on protein function (PMID: 15461624; PS3). At least 1 patient (Patient B) with this variant displayed

excessive mucocutaneous bleeding as well as low FVIII activity (20 IU/dl) and dramatically decreased VWF:FVIII binding, which is highly specific for VWD type 2N. (PP4_moderate, PMID:15213842). Patient B (PMID: 15461624) is compound heterozygous for R854Q (classified Pathogenic by the VWD VCEP; PM3_supporting). In summary, this variant meets the criteria to be classified as Likely Pathogenic for von Willebrand disease type 2N. ACMG/AMP criteria applied as specified by the ClinGen von Willebrand disease Variant Curation Expert Panel: PM2_supporting, PP3, PM3_supporting, PP4_moderate, PS3.

Met criteria codes

PP3 ✔	The computational predictor REVEL gives a score of 0.935, which is above the ClinGen VWD VCEP threshold of >0.644 and predicts a damaging effect on VWF function (PP3).
PM3_Supporting ✔	Patient B (PMID: 15461624) is compound heterozygous for R854Q (classified Pathogenic by the VWD VCEP) and C804F; confirmation of trans phase was not reported. 0.5pt (PM3_supporting).
PM2_Supporting ✔	This variant is absent from gnomAD v4.1 (PM2_Supporting).
PP4_Moderate ✔	At least 1 patient with this variant displayed excessive mucocutaneous bleeding as well as low FVIII activity (20 IU/dl) and dramatically decreased VWF:FVIII binding, which is highly specific for VWD type 2N. (PP4_moderate, PMID:15213842).
PS3 ✔	Factor VIII binding assay performed with the C804F recombinant mutant showed severely impaired binding indicating that this variant has a damaging effect on protein function (PMID: 15461624; PS3).

Expression studies in Cos-7 cells showed C804F failed to bind FVIII. **PubMed:15461624**

Curation History

Showing 1 to 1 of 1 rows

See Report	Preferred Variant Title	Classification	Condition	Published Date	Version	Criteria Specification	Gene
View	NM_000552.5(VWF):c.2411G>T (p.Cys...	Likely Pathogenic	Von Willebrand Disease Type 2N	2025-02-05	1.0	ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF Version 1.0.0	VWF

Showing 1 to 1 of 1 rows

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.